Inhibikase Therapeutics, Inc. reported its financial results for the year ended December 31, 2024, on March 27, 2025. The company recorded a net loss of $27.5 million, or $1.16 per share, for the full year.
This compares to a net loss of $19.1 million, or $3.16 per share, for the year ended December 31, 2023. Research and development expenses increased to $17.2 million in 2024, up from $13.6 million in 2023.
Selling, general and administrative expenses also rose to $11.4 million for the year, compared to $6.7 million in 2023. As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $97.5 million.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.